immunotherapy world

Conference

Immunotherapy has been an emerging and exciting therapeutic area that has experienced massive growth in terms of research and development expenditures and the sheer number of clinical trials. Analysts have projected that the cancer immunotherapy market will increase to nearly $9 billion across the world's major pharmaceutical markets by 2022 (the whole cancer drug market is expected to reach $111.9bn (Allied Market Research), so immuno-oncology will be within the region of 10% market share for this type of therapeutic).

Immunotherapies may eventually be used in as many as 60% of cases of advanced cancer, and are likely to see their first applications in melanoma, NSCLC, and B-cell malignancies. Either alone or in combination therapies, immunotherapies may produce long-term remissions or even cures for cancers that have been uniformly fatal until very recently. 

 


Take a look at who was in the room at our industry’s leading exhibition last year – CLICK HERE.

Over 80 leading VPs (and above) will discuss the unique talking points in this rapidly evolving field:

  • How far have we come? Evaluating the magnitude of immuno-oncology at this stage
  • Reviewing Immuno-Oncology: What works and what doesn’t? What are the future directions?
  • Precision Immunology/Oncology: There has been a ‘changing paradigm’ to how we approach cancer treatment in the modern era. Clinicans/researchers want to determine the unique genetic changes in an individual patient’s cancer, as well as their immune profile, in order to appropriate immunotherapy to treat specific cancers. How we can help practicing oncologists be thoroughly familiar with the clinical application of targeted therapy and tumour immunotherapy to provide high-quality cancer care in this new era.
  • Combination therapies: As described at ASCO, combinational approaches have brought response rates to about 30%, but now investigators need to identify what the additional mechanisms of resistance are. How can new drugs or development platforms overcome resistance and restore a functional immune-surveillance system by leveraging multiple, complementary mechanisms of action, acting on multiple phases of the cancer-immunity cycle?
  • Types of combination approaches – 1. Adoptive T cell therapy, 2. Combinations in Immune Checkpoint blockade (eg. stimulatory and inhibition), 3. Oncolytic virus therapy, 4. Cancer Vaccines, 5. Targeted therapies, 6. Small molecules
  • Bispecific molecules: These antibodies are engineered to bind to two different types of antigen at the same time. In practice, this can mean one arm can engage the immune system and the other one is a dual targeting of a tumour cell.
  • Using bioinformatics to predict response: Next-generation sequencing technologies are increasingly being implemented for molecular prescreening in clinical research. Harnessing genomic, transcriptomic and immunological data from clinical cohorts of immunotherapy-treated patients to bring the promise of precision medicine to immune-oncology
  • Overcoming the challenges facing translational development in Immuno-Oncology: With the emerging understanding of the individual nature of cancer, how can we drive successes and overcome shortcomings of available preclinical models? How can we effectively drive investigations into new, novel & multiple therapeutic targets from the lab into the clinic in order to widen treatment response in this drug class?
  • Refining immune endpoints to better inform clinical trial design: How do we better understand response patterns to evaluate clinical endpoints in immunotherapy? Reviewing the immuno-dynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and intra-tumoral. This discussion includes the use of imaging to fully characterize the patterns of immune-related phenomena to understand these patterns across multiple tumor types.
  • Characterizing complex interactions to decipher clinical relevant biomarkers: The advent of the immunotherapy revolution demands multi-omics strategies for biomarker discovery and companion diagnostics development because immune-oncology therapeutics elicit multifaceted changes to the tumor cells and the immune systems.
  • Characterizing the appropriate safety profile of immuno-oncology agents: How the FDA is tackling regulatory and safety concerns when two or more unapproved drugs are combined and identifying regulatory pathways for combinations
  • How emerging science will evolve partnerships and licensing agreements for immuno-oncology: What criteria are major I-O players using to choose their different cancer immunotherapy combinations across the industry? Leveraging partnerships to drive growth towards commercial success
  • The clinical and reimbursement landscape of immuno-oncology: Under significant pressure to reduce the burden of cancer spending (eg. the value-based care delivery legislation that is being brought in), payers are beginning to make bold network decisions and looking at the application of precision tools to ensure the quality of care is uncompromised, and even improved, while reining in unsustainable cost trends. What are the implications for firms investing in Immuno-Oncology?
  • Venture capital in the sector: Long-term strategic and capital allocation questions for cancer R&D

 

Featured Speakers


 

It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer.

Lance Leopold MD, Vice President, Head of Oncology Development, Incyte Corporation

Attending pharma/biotech companies include

  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • adaptimm
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • aldevron
  • allele
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • apogenix
  • arthrogen
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • g con
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • genvec
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Incyte
  • Attending Pharma/Biotech companies Cell & Gene Therapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Miami Attending companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • Miami Attending companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • takara
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • Attending Pharma/Biotech companies Immunotherapy World
  • arending companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • vcls
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • Attending Pharma/Biotech companies Immunotherapy World
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • attending pharma/biotech companies
  • world care
  • attending pharma/biotech companies
  • attending pharma/biotech companies